It is a
designer drug and an NPS (short for "new psychoactive substance").[1] At the end of 2017, cloniprazepam was an uncontrolled substance in most of the countries.
^
abcMoosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). "Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam". Journal of Mass Spectrometry. 51 (11): 1080–1089.
Bibcode:
2016JMSp...51.1080M.
doi:
10.1002/jms.3840.
PMID27535017.
^Mortelé O, Vervliet P, Gys C, Degreef M, Cuykx M, Maudens K, et al. (May 2018). "In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry". Journal of Pharmaceutical and Biomedical Analysis. 153: 158–167.
doi:
10.1016/j.jpba.2018.02.032.
hdl:10067/1496330151162165141.
PMID29494888.
S2CID3946404.